Sitagliptin - Wikipedia
Sitagliptin, sold under the brand name Januvia among others, is an anti-diabetic medication used to treat type 2 diabetes. [8] In the United Kingdom it is listed as less preferred than metformin or a sulfonylurea. [9] It is taken by mouth. [8] It is also available in the fixed-dose combination medication sitagliptin/metformin (Janumet, Janumet ...
Dipeptidyl Peptidase IV (DPP IV) Inhibitors - StatPearls - NCBI Bookshelf
2023年5月22日 · DPP-4 inhibitors, known as gliptins, are a class of oral diabetic medications approved by the Food and Drug Administration (FDA) to treat type 2 diabetes mellitus in adults. DPP-4 inhibitors that have FDA approval include sitagliptin, saxagliptin, linagliptin, and alogliptin.
Sitagliptin: Uses, Interactions, Mechanism of Action
Sitagliptin may decrease the excretion rate of Valbenazine which could result in a higher serum level. Valdecoxib The therapeutic efficacy of Sitagliptin can be increased when used in combination with Valdecoxib.
UpToDate
This topic will review the mechanism of action and therapeutic utility of DPP-4 inhibitors for the treatment of type 2 diabetes mellitus. GLP-1 receptor agonists are discussed separately.
SitaGLIPtin: Dosage, Mechanism/Onset of Action, Half-Life
Januvia: 25 mg, 50 mg, 100 mg. Sitagliptin inhibits dipeptidyl peptidase-4 (DPP-4) enzyme resulting in prolonged active incretin levels.
Mechanism of Action of DPP-4 Inhibitors—New Insights - PMC
Sitagliptin resulted in greater suppression of endogenous glucose production and decreased meal appearance. This was attributed to improved β-cell function and decreased glucagon concentrations. Intriguingly, their data suggested a beneficial effect of …
JANUVIA is a dipeptidyl peptidase-4 (DPP-4) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Review of sitagliptin phosphate: a novel treatment for type 2 diabetes
2007年3月2日 · Sitagliptin is effective in lowering HbA1c, and fasting as well as postprandial glucose in monotherapy and in combination with other oral antidiabetic agents. It stimulates insulin secretion when hyperglycemia is present and inhibits glucagon secretion. In clinical studies it is weight neutral.
Sitagliptin: A Review in Type 2 Diabetes - PubMed
The dipeptidyl peptidase-4 inhibitor sitagliptin (Januvia ®; Glactiv ®; Tesavel ®; Xelevia™) is approved in more than 130 countries worldwide as monotherapy and in combination with other antihyperglycaemic drugs for the treatment of adult patients with type 2 diabetes (T2D).
SITagliptin Monograph for Professionals - Drugs.com
2024年6月11日 · Antidiabetic agent; dipeptidyl peptidase-4 (DPP-4) inhibitor. Used as monotherapy as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus.